The PBAC has recommended that filgrastim (Neupogen) and its three biosimilars (Nivestim, Tevagrastim and Zarzio) can be marked as equivalent for the purposes of substitution. The decision, made at the PBAC’s April meeting and reported last week, applies to all indications including treatment of chemotherapy-induced and other neutropenias or for mobilisation of peripheral blood progenitor ...
Filgrastim products ruled bioequivalent
By Mardi Chapman
13 Jun 2018